Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchHH-120HH-120 (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Nasal spray of an IgM‐like ACE2 fusion protein HH‐120 accelerates SARS‐CoV‐2 clearance: A single‐center propensity score‐matched cohort study

Song et al., Journal of Medical Virology, doi:10.1002/jmv.28805
May 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Time to viral- 20% Improvement Relative Risk Time to viral-, higher base.. 29% HH-120 for COVID-19  Song et al.  LATE TREATMENT Is late treatment with HH-120 beneficial for COVID-19? PSM retrospective 168 patients in China (August - October 2022) Faster viral clearance with HH-120 (p=0.001) c19early.org Song et al., J. Medical Virology, May 2023 FavorsHH-120 Favorscontrol 0 0.5 1 1.5 2+
PSM analysis of 65 HH-120 patients and 103 controls contemporaneously hospitalized in the same hospital, showing faster viral clearance with HH-120 treatment, with improved results for patients with higher baseline viral load.
time to viral-, 20.0% lower, relative time 0.80, p = 0.001, treatment 65, control 103, propensity score matching.
time to viral-, 28.6% lower, relative time 0.71, p = 0.001, higher baseline viral load, propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Song et al., 25 May 2023, retrospective, China, peer-reviewed, 13 authors, study period 3 August, 2022 - 7 October, 2022.
This PaperHH-120All
{ 'indexed': {'date-parts': [[2023, 12, 6]], 'date-time': '2023-12-06T18:08:50Z', 'timestamp': 1701886130182}, 'reference-count': 44, 'publisher': 'Wiley', 'issue': '5', 'license': [ { 'start': { 'date-parts': [[2023, 5, 25]], 'date-time': '2023-05-25T00:00:00Z', 'timestamp': 1684972800000}, 'content-version': 'vor', 'delay-in-days': 24, 'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor'}], 'content-domain': {'domain': ['onlinelibrary.wiley.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2023, 5]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec><jats:label /><jats:p>HH‐120, a recently developed ' 'IgM‐like ACE2 fusion protein with broad‐spectrum neutralizing activity against all ' 'ACE2‐utilizing coronaviruses, has been developed as a nasal spray for use as an early ' 'treatment agent to reduce disease progression and airborne transmission. The objective of ' 'this study was to evaluate the safety and efficacy of the HH‐120 nasal spray in ' 'SARS‐CoV‐2‐infected subjects. Eligible symptomatic or asymptomatic SARS‐CoV‐2‐infected ' 'participants were enrolled in a single‐arm trial to receive the HH‐120 nasal spray for no ' 'longer than 6 days or until viral clearance at a single hospital between August 3 and October ' '7, 2022. An external control was built from real‐world data of SARS‐CoV‐2‐infected subjects ' 'contemporaneously hospitalized in the same hospital using a propensity score matching (PSM) ' 'method. After PSM, 65 participants in the HH‐120 group and 103 subjects with comparable ' 'baseline characteristics in the external control group were identified. The viral clearance ' 'time was significantly shorter in participants receiving the HH‐120 nasal spray than that in ' 'subjects of the control group (median 8 days vs. 10 days, <jats:italic>p</jats:italic>\u2009' '&lt;\u20090.001); the difference was more prominent in those subgroup subjects with higher ' 'baseline viral load (median 7.5 days vs. 10.5 days, <jats:italic>p</jats:italic>\u2009' '&lt;\u20090.001). The incidence of treatment‐emergent adverse events\xa0and treatment‐related ' 'adverse events\xa0of HH‐120 group were 35.1% (27/77) and 3.9% (3/77), respectively. All the ' 'adverse events observed were mild, being of CTCAE grade 1 or 2, and transient. The HH‐120 ' 'nasal spray showed a favorable safety profile and promising antiviral efficacy in ' 'SARS‐CoV‐2‐infected subjects. The results from this study warrant further assessment of the ' 'efficacy and safety of the HH‐120 nasal spray in large‐scale randomized controlled clinical ' 'trials.</jats:p></jats:sec>', 'DOI': '10.1002/jmv.28805', 'type': 'journal-article', 'created': {'date-parts': [[2023, 5, 25]], 'date-time': '2023-05-25T11:54:04Z', 'timestamp': 1685015644000}, 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 2, 'title': 'Nasal spray of an IgM‐like ACE2 fusion protein HH‐120 accelerates SARS‐CoV‐2 clearance: A ' 'single‐center propensity score‐matched cohort study', 'prefix': '10.1002', 'volume': '95', 'author': [ { 'given': 'Rui', 'family': 'Song', 'sequence': 'first', 'affiliation': [{'name': 'Beijing Ditan Hospital Capital Medical University Beijing China'}]}, { 'given': 'Xiaoyou', 'family': 'Chen', 'sequence': 'additional', 'affiliation': [{'name': 'Beijing Ditan Hospital Capital Medical University Beijing China'}]}, { 'given': 'Baoliang', 'family': 'Li', 'sequence': 'additional', 'affiliation': [{'name': 'Beijing Ditan Hospital Capital Medical University Beijing China'}]}, { 'given': 'Hongbin', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': [{'name': 'Huahui Health Ltd. Beijing China'}]}, { 'given': 'Xiaodi', 'family': 'Guo', 'sequence': 'additional', 'affiliation': [{'name': 'Beijing Ditan Hospital Capital Medical University Beijing China'}]}, { 'given': 'Zhe', 'family': 'Liu', 'sequence': 'additional', 'affiliation': [{'name': 'Beijing Ditan Hospital Capital Medical University Beijing China'}]}, { 'given': 'Liangfeng', 'family': 'Zou', 'sequence': 'additional', 'affiliation': [{'name': 'Huahui Health Ltd. Beijing China'}]}, { 'given': 'Xiao', 'family': 'Liang', 'sequence': 'additional', 'affiliation': [{'name': 'Huahui Health Ltd. Beijing China'}]}, { 'given': 'Cong', 'family': 'Lei', 'sequence': 'additional', 'affiliation': [{'name': 'Huahui Health Ltd. Beijing China'}]}, { 'given': 'Fengfeng', 'family': 'Mao', 'sequence': 'additional', 'affiliation': [{'name': 'Huahui Health Ltd. Beijing China'}]}, { 'given': 'Jianhua', 'family': 'Sui', 'sequence': 'additional', 'affiliation': [ {'name': 'National Institute of Biological Sciences Beijing China'}, { 'name': 'Tsinghua Institute of Multidisciplinary Biomedical Research ' 'Tsinghua University Beijing China'}]}, { 'given': 'Wenhui', 'family': 'Li', 'sequence': 'additional', 'affiliation': [ {'name': 'National Institute of Biological Sciences Beijing China'}, { 'name': 'Tsinghua Institute of Multidisciplinary Biomedical Research ' 'Tsinghua University Beijing China'}]}, { 'given': 'Ronghua', 'family': 'Jin', 'sequence': 'additional', 'affiliation': [ {'name': 'Beijing Ditan Hospital Capital Medical University Beijing China'}, { 'name': 'National Center for Infectious Diseases, Beijing Ditan Hospital ' 'Capital Medical University Beijing China'}, { 'name': 'Institute of Infectious Diseases, Beijing Key Laboratory of ' 'Emerging Infectious Diseases, Beijing Ditan Hospital Capital ' 'Medical University Beijing China'}]}], 'member': '311', 'published-online': {'date-parts': [[2023, 5, 25]]}, 'reference': [ {'key': 'e_1_2_9_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2034577'}, {'key': 'e_1_2_9_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2029849'}, {'key': 'e_1_2_9_4_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2107934'}, {'key': 'e_1_2_9_5_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2035002'}, {'key': 'e_1_2_9_6_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2116846'}, {'key': 'e_1_2_9_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2118542'}, {'key': 'e_1_2_9_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2116044'}, { 'key': 'e_1_2_9_9_1', 'unstructured': 'WHO.\xa02023. Weekly epidemiological update on COVID‐19 ‐ 22 February. ' 'Accessed February 27 2023.\xa0' 'https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---22-february-2023.'}, {'key': 'e_1_2_9_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-021-04388-0'}, { 'key': 'e_1_2_9_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S1473-3099(22)00663-6'}, { 'issue': '7948', 'key': 'e_1_2_9_12_1', 'first-page': '521', 'article-title': 'Imprinted SARS‐CoV‐2 humoral immunity induces convergent Omicron RBD ' 'evolution', 'volume': '614', 'author': 'Cao Y', 'year': '2023', 'journal-title': 'Nature'}, {'key': 'e_1_2_9_13_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cell.2022.12.018'}, { 'key': 'e_1_2_9_14_1', 'doi-asserted-by': 'crossref', 'unstructured': 'TamuraT ItoJ UriuK et al.Virological characteristics of the SARS‐CoV‐2 ' 'XBB variant derived from recombination of two Omicron ' 'subvariants.bioRxiv. Preprint posted online December 27 ' '2022.doi:10.1101/2022.12.27.521986', 'DOI': '10.1101/2022.12.27.521986'}, {'key': 'e_1_2_9_15_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-020-2012-7'}, {'key': 'e_1_2_9_16_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cell.2020.02.052'}, {'key': 'e_1_2_9_17_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/nature02145'}, {'key': 'e_1_2_9_18_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/science.1116480'}, {'key': 'e_1_2_9_19_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-022-05513-3'}, { 'key': 'e_1_2_9_20_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/scitranslmed.abn7737'}, {'key': 'e_1_2_9_21_1', 'doi-asserted-by': 'publisher', 'DOI': '10.15252/emmm.202216109'}, {'key': 'e_1_2_9_22_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/science.abe0075'}, {'key': 'e_1_2_9_23_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cell.2020.04.004'}, {'key': 'e_1_2_9_24_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41467-021-24013-y'}, {'key': 'e_1_2_9_25_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.tips.2022.06.011'}, {'key': 'e_1_2_9_26_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/sciadv.abq6527'}, { 'key': 'e_1_2_9_27_1', 'doi-asserted-by': 'crossref', 'unstructured': 'LiW LiuJ MaoF et al.An IgM‐like inhalable ACE2 fusion protein broadly ' 'neutralizes SARS‐CoV‐2.Research Square. Preprint posted online October ' '31 2022.doi:10.21203/rs.3.rs-2044084/v1', 'DOI': '10.21203/rs.3.rs-2044084/v1'}, { 'key': 'e_1_2_9_28_1', 'doi-asserted-by': 'publisher', 'DOI': '10.4049/jimmunol.154.5.2226'}, {'key': 'e_1_2_9_29_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cell.2022.11.030'}, { 'key': 'e_1_2_9_30_1', 'doi-asserted-by': 'crossref', 'unstructured': 'LuG LingY JiangM et al.Primary assessment of the diversity of omicron ' 'sublineages and the epidemiologic features of autumn/winter 2022 ' 'COVID‐19 wave in Chinese mainland.Front ' 'Med.2023:1‐10.https://doi.org/10.1007/s11684-022-0981-7', 'DOI': '10.1007/s11684-022-0981-7'}, { 'key': 'e_1_2_9_31_1', 'unstructured': 'US Department of Health and Human Services.\xa0Common terminology ' 'criteria for adverse events. Version 5.0. November 27 2017.'}, { 'key': 'e_1_2_9_32_1', 'doi-asserted-by': 'crossref', 'unstructured': 'HoDE ImaiK KingG StuartEA.MatchIt: nonparametric preprocessing for ' 'parametric causal inference.J Stat Softw.2011;42(8).', 'DOI': '10.18637/jss.v042.i08'}, {'key': 'e_1_2_9_33_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/vaccines10091409'}, { 'key': 'e_1_2_9_34_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/22221751.2022.2078230'}, {'key': 'e_1_2_9_35_1', 'doi-asserted-by': 'publisher', 'DOI': '10.7554/eLife.81849'}, {'key': 'e_1_2_9_36_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s00405-020-06457-y'}, { 'key': 'e_1_2_9_37_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/scitranslmed.abl7430'}, {'key': 'e_1_2_9_38_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/irv.13095'}, { 'key': 'e_1_2_9_39_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2666-5247(23)00011-3'}, {'key': 'e_1_2_9_40_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cell.2022.05.005'}, { 'key': 'e_1_2_9_41_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(22)00327-0'}, {'key': 'e_1_2_9_42_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/science.abf4896'}, {'key': 'e_1_2_9_43_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMc2209651'}, {'key': 'e_1_2_9_44_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/gutjnl-2021-326792'}, { 'key': 'e_1_2_9_45_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.aohep.2022.100763'}], 'container-title': 'Journal of Medical Virology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.28805', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 8, 20]], 'date-time': '2023-08-20T08:31:37Z', 'timestamp': 1692520297000}, 'score': 1, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1002/jmv.28805'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 5]]}, 'references-count': 44, 'journal-issue': {'issue': '5', 'published-print': {'date-parts': [[2023, 5]]}}, 'alternative-id': ['10.1002/jmv.28805'], 'URL': 'http://dx.doi.org/10.1002/jmv.28805', 'relation': {}, 'ISSN': ['0146-6615', '1096-9071'], 'subject': ['Infectious Diseases', 'Virology'], 'container-title-short': 'Journal of Medical Virology', 'published': {'date-parts': [[2023, 5]]}, 'assertion': [ { 'value': '2023-02-27', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2023-05-08', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2023-05-25', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit